Yilan Hu , Weihang Zhang , Shah Rukh Ali , Koji Takeda , Torsten Peter Vahl , Donghui Zhu , Yi Hong , Ke Cheng
{"title":"Extracellular vesicle therapeutics for cardiac repair","authors":"Yilan Hu , Weihang Zhang , Shah Rukh Ali , Koji Takeda , Torsten Peter Vahl , Donghui Zhu , Yi Hong , Ke Cheng","doi":"10.1016/j.yjmcc.2024.11.005","DOIUrl":"10.1016/j.yjmcc.2024.11.005","url":null,"abstract":"<div><div>Extracellular vesicles (EVs) are cell-secreted heterogeneous vesicles that play crucial roles in intercellular communication and disease pathogenesis. Due to their non-tumorigenicity, low immunogenicity, and therapeutic potential, EVs are increasingly used in cardiac repair as cell-free therapy. There exist multiple steps for the design of EV therapies, and each step offers many choices to tune EV properties. Factors such as EV source, cargo, loading methods, routes of administration, surface modification, and biomaterials are comprehensively considered to achieve specific goals. PubMed and Google Scholar were searched in this review, 89 articles related to EV-based cardiac therapy over the past five years (2019 Jan - 2023 Dec) were included, and their key steps in designing EV therapies were counted and analyzed. We aim to provide a comprehensive overview that can serve as a reference guide for researchers to design EV-based cardiac therapies.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 12-32"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jin Guan , Nadezhda Fefelova , Peiyong Zhai , Yoshiyuki Ikeda , Takanobu Yamamoto , Satvik Mareedu , Jamie Francisco , Lai-Hua Xie , Dae-sik Lim , Dominic P. Del Re
{"title":"Dual inhibition of Mst1 and Mst2 exacerbates cardiac dysfunction during pressure overload stress in mice","authors":"Jin Guan , Nadezhda Fefelova , Peiyong Zhai , Yoshiyuki Ikeda , Takanobu Yamamoto , Satvik Mareedu , Jamie Francisco , Lai-Hua Xie , Dae-sik Lim , Dominic P. Del Re","doi":"10.1016/j.yjmcc.2024.12.009","DOIUrl":"10.1016/j.yjmcc.2024.12.009","url":null,"abstract":"<div><div>Heart failure remains a leading cause of morbidity and mortality worldwide. The evolutionarily conserved Hippo-Yap signaling pathway regulates cardiac responses to stress and progression to heart failure. Mst1 and Mst2 are the core Hippo pathway kinases, yet their role within chronically stressed cardiomyocytes remains largely unknown. Genetic mouse models revealed that the extent of Mst1/2 inhibition elicits opposing effects on stress-induced cardiac dysfunction. Yap-TEAD1 activation, cell cycling, and hallmarks of cardiomyocyte dedifferentiation, which can impair contractile function during sustained stress, were enhanced in Mst1/2 double knockout hearts. These findings implicate a physiological function of Mst1/2 to promote cardiomyocyte maturity in the adult heart.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 133-136"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lu Wang , Wanyue Sang , Yi Jian , Yafan Han , Feifei Wang , Subinuer Wubulikasimu , Li Yang , Baopeng Tang , Yaodong Li
{"title":"MAPK14/AIFM2 pathway regulates mitophagy-dependent apoptosis to improve atrial fibrillation","authors":"Lu Wang , Wanyue Sang , Yi Jian , Yafan Han , Feifei Wang , Subinuer Wubulikasimu , Li Yang , Baopeng Tang , Yaodong Li","doi":"10.1016/j.yjmcc.2024.12.002","DOIUrl":"10.1016/j.yjmcc.2024.12.002","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate the role and mechanism of MAPK14/AIFM2 pathway in Ang II-induced atrial fibrillation in rats.</div></div><div><h3>Methods</h3><div>A rat model of AF was established for in vivo experiments and HL-1 cells were treated with Ang II to develop an in vitro model. In addition, HL1 cells overexpressing AIFM2 (oeAIFM2) were constructed. SB203580 was used to inhibit the expression of MAPK14. The role of MAPK14 in Ang II-AF model was investigated by in vivo electrophysiological examination and molecular biology tests. The role of MAPK14 / AIFM2 pathway on AF induced by Ang II was explored in vitro.</div></div><div><h3>Results</h3><div>MAPK14 and AIFM2 were significantly up-regulated in AF induced by Ang II (all <em>P</em> < 0.05). In vivo experiments indicated that inhibition of MAPK14 down-regulated AIFM2, improved atrial electrical conduction, AF inducibility and durations, and alleviated the structural and functional damage of heart and mitochondria (all <em>P</em> < 0.05). Both in vivo and in vitro tests showed that the MAPK14/AIFM2 pathway prevented Ang II-induced AF via regulating mitophagy-dependent apoptosis.</div></div><div><h3>Conclusions</h3><div>Inhibition of the MAPK14/AIFM2 pathway improved Ang II-induced AF by inhibiting mitophagy-dependent apoptosis.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 1-11"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yongqi Wu , Yujuan Song , Nan Xie , Wanqing Zhao , Jian Lv , Tingting Zhang , Yang Zhang , Hongyin Chen , Weiyun Sun , Zhenyu Luo , Xinhui Cheng , Tao Jiang , Zhihua Wang , Xiaoling Chen , Yu Hu , Yu Fang , Rui Bai , Xujie Liu , Xia He , Zongna Ren , Li Wang
{"title":"KLF2-dependent transcriptional regulation safeguards the heart against pathological hypertrophy","authors":"Yongqi Wu , Yujuan Song , Nan Xie , Wanqing Zhao , Jian Lv , Tingting Zhang , Yang Zhang , Hongyin Chen , Weiyun Sun , Zhenyu Luo , Xinhui Cheng , Tao Jiang , Zhihua Wang , Xiaoling Chen , Yu Hu , Yu Fang , Rui Bai , Xujie Liu , Xia He , Zongna Ren , Li Wang","doi":"10.1016/j.yjmcc.2024.12.010","DOIUrl":"10.1016/j.yjmcc.2024.12.010","url":null,"abstract":"<div><h3>Background</h3><div>Our previous single-cell RNA sequencing study in the adult human heart revealed that cardiomyocytes from both the atrium and ventricle display high activities of Krüppel-like factor 2 (KLF2) regulons. However, the role of the transcription factor KLF2 in cardiomyocyte biology remains largely unexplored.</div></div><div><h3>Methods and results</h3><div>We employed transverse aortic constriction surgery in male C57BL/6 J mice to develop an <em>in vivo</em> model of cardiac hypertrophy, and generated different <em>in vitro</em> cardiac hypertrophy models in neonatal rat ventricular myocytes and human embryonic stem cell-derived cardiomyocytes. Our results demonstrated a significant reduction in KLF2 expression during the progression of cardiac hypertrophy. <em>In vitro</em>, <em>Klf2</em> deficiency exacerbates cardiac hypertrophy and enhances hypertrophic reprogramming, while KLF2 overexpression attenuates cardiac hypertrophy and reverses hypertrophic transcriptome reprogramming. Mechanistically, combined RNA-seq and cleavage under targets & tagmentation (CUT&Tag) analysis revealed that KLF2 exerts its protective effects by directly regulating a set of genes associated with cardiac hypertrophy. <em>In vivo</em>, KLF2 overexpression specifically in cardiomyocytes effectively prevents TAC-induced cardiac hypertrophy in mice. Additionally, we found that simvastatin elevates KLF2 expression in cardiomyocytes, which subsequently alleviates cardiomyocyte hypertrophy.</div></div><div><h3>Conclusions</h3><div>This study provides the first evidence that transcription factor KLF2 serves as a negative regulator of cardiac hypertrophy. Our findings highlight the therapeutic potential of enhancing KLF2 expression, particularly through simvastatin administration, as a promising strategy in the treatment of cardiac hypertrophy.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 62-77"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Satadru K. Lahiri , Stephan E. Lehnart , Svetlana Reilly , Xander H.T. Wehrens
{"title":"Response to commentary from Song et al.","authors":"Satadru K. Lahiri , Stephan E. Lehnart , Svetlana Reilly , Xander H.T. Wehrens","doi":"10.1016/j.yjmcc.2025.01.002","DOIUrl":"10.1016/j.yjmcc.2025.01.002","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 78-79"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jing Fu , Li Li , Long Chen , Congping Su , Xiuling Feng , Kai Huang , Laxi Zhang , Xiaoyan Yang , Qin Fu
{"title":"Corrigendum to “PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2” [Journal of Molecular and Cellular Cardiology. 172(2022) 63–77]","authors":"Jing Fu , Li Li , Long Chen , Congping Su , Xiuling Feng , Kai Huang , Laxi Zhang , Xiaoyan Yang , Qin Fu","doi":"10.1016/j.yjmcc.2024.11.003","DOIUrl":"10.1016/j.yjmcc.2024.11.003","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Page 80"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gregory Farber , Paige Takasugi , Shea Ricketts , Haofei Wang , Yifang Xie , Esther Farber , Jiandong Liu , Li Qian
{"title":"Sox17 and Erg synergistically activate endothelial cell fate in reprogramming fibroblasts","authors":"Gregory Farber , Paige Takasugi , Shea Ricketts , Haofei Wang , Yifang Xie , Esther Farber , Jiandong Liu , Li Qian","doi":"10.1016/j.yjmcc.2024.11.012","DOIUrl":"10.1016/j.yjmcc.2024.11.012","url":null,"abstract":"<div><div><em>Sox17-Erg</em> direct reprogramming is a potent tool for the in vitro and in vivo generation of arterial-like induced-endothelial cells from fibroblasts. In this study, we illustrate the pioneering roles of both <em>Sox17</em> and <em>Erg</em> in the endothelial cell reprogramming process and demonstrate that emergent gene expression only occurs when both factors are co-expressed. Bioinformatic analyses and molecular validation reveal both <em>Bach2</em> and <em>Etv4</em> as integral mediators of <em>Sox17-Erg</em> reprogramming with different roles in lung and heart fibroblast reprogramming. The generated organ-specific induced endothelial cells express molecular signatures similar to vasculature found in the starting cell's organ of origin and the starting chromatin architecture plays a role in the acquisition of this organ-specific identity. Overall, the <em>Sox17-Erg</em> reprogramming mechanism provides foundational knowledge for the future recapitulation of vascular heterogeneity through direct reprogramming.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"199 ","pages":"Pages 33-45"},"PeriodicalIF":4.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Parisa Shabani, Feng Dong, June Yun, Song Yi Shin, Amber Dinchman, Dipan Kundu, Adam Goodwill, James Gadd, Thomas Pucci, Christopher Kolz, Lindsay Shockling, Liya Yin, William Chilian, Vahagn Ohanyan
{"title":"Does coronary microvascular dysfunction play a role in heart failure with reduced ejection fraction?","authors":"Parisa Shabani, Feng Dong, June Yun, Song Yi Shin, Amber Dinchman, Dipan Kundu, Adam Goodwill, James Gadd, Thomas Pucci, Christopher Kolz, Lindsay Shockling, Liya Yin, William Chilian, Vahagn Ohanyan","doi":"10.1016/j.yjmcc.2025.01.007","DOIUrl":"10.1016/j.yjmcc.2025.01.007","url":null,"abstract":"<div><div>Heart failure (HF) is a conundrum in that, current therapies only slow the progression of the disease. We posit, if the causal mechanism were targeted, progression of the disease could be stopped and potentially reversed. We hypothesize that insufficient myocardial blood flow (MBF) produces minute areas of ischemia, that lead to an accumulating injury culminating in HF. Accordingly, we determined the relationship between MBF and cardiac work (wall stress-rate product [WSRP]) in control C57Bl6/J mice (Control), mice with transaortic constriction to produce HF (TAC-HF) and HF mice treated with the coronary vasodilator, chromonar (4 weeks of treatment, TAC-Chromonar). MBF and WSRP were measured during norepinephrine infusion in anesthetized mice. In Controls, MBF increased when work/WSRP was increased with norepinephrine, however, when cardiac work was increased in TAC-HF, MBF did not increase. After chromonar treatment, when work increased, MBF increased. Changes in cardiac function paralleled MBF, i.e., decrement in cardiac function occurred in TAC-HF (ejection fraction), but 4 weeks of chromonar treatment reversed this functional decline. We also found in a model of cardiac hypoxia fate-mapping, a 5-fold increase in the number of hypoxic cardiac myocytes (TAC-HF vs Control), which was reversed by chromonar. Capillary densities also followed this trend with a decrease from Control in TAC-HF, which was restored by Chromonar. We propose that a cause of HF is inadequate MBF to meet the metabolic demands of the working heart. Pharmacological coronary vasodilation with chromonar to increase MBF in HF can reverse the functional decline and improve cardiac function.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"200 ","pages":"Pages 61-67"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Langtao Wang , Jiarou Song , Zhen Yang , Hailong Zhang , Yaping Wang , Jin Liu , Sai Wang , Jian Shi , Xiaoyong Tong
{"title":"SERCA2 dysfunction accelerates angiotensin II-induced aortic aneurysm and atherosclerosis by induction of oxidative stress in aortic smooth muscle cells","authors":"Langtao Wang , Jiarou Song , Zhen Yang , Hailong Zhang , Yaping Wang , Jin Liu , Sai Wang , Jian Shi , Xiaoyong Tong","doi":"10.1016/j.yjmcc.2025.01.009","DOIUrl":"10.1016/j.yjmcc.2025.01.009","url":null,"abstract":"<div><h3>Background and aim</h3><div>Our previous research indicates that sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) dysfunction facilitates the phenotypic transformation of aortic smooth muscle cells (ASMCs) and intensifies aortic aneurysm through the regulation of calcium-dependent pathways and endoplasmic reticulum stress. Our hypothesis is that additional mechanisms are involved in aortic aneurysm and atherosclerosis induced by SERCA2 dysfunction from the perspective of ASMC phenotypic transformation.</div></div><div><h3>Methods & results</h3><div>In SERCA2 dysfunctional mice and their control littermates, ASMCs were isolated to analyze protein expression and cell functions, and angiotensin II was infused into these mice that were backcrossed into LDL receptor deficient background to induce aortic aneurysm and atherosclerosis. In ASMCs from SERCA2 dysfunctional mice, the cell cycle was accelerated, and proliferation and migration were enhanced, which could be reversed by SERCA agonist CDN1163 or calcium chelator BAPTA-AM. In ASMCs, SERCA2 dysfunction increased reactive oxygen species (ROS) production, activating extracellular signal-regulated kinases 1 and 2 (ERK1/2) and angiotensin II/angiotensin II type 1 receptor (AT1R) pathways. Both ERK1/2 and angiotensin II/AT1R activations are implicated in SERCA2 dysfunction-induced ASMC phenotypic transformation and ROS production. The redox modulator Tempol suppressed ERK1/2 and angiotensin II/AT1R pathways, inhibiting ASMC phenotypic transformation and alleviating angiotensin II-induced aortic aneurysm and atherosclerosis.</div></div><div><h3>Conclusion</h3><div>SERCA2 dysfunction accelerates aortic aneurysm and atherosclerosis by inducing oxidative stress in ASMCs, with activations of ERK1/2 and angiotensin II/AT1R involved in ASMC phenotypic transformation. Inhibition of oxidative stress in ASMCs is beneficial in alleviating angiotensin II-induced aortic aneurysm and atherosclerosis caused by SERCA2 dysfunction.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"200 ","pages":"Pages 68-81"},"PeriodicalIF":4.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}